Mankind Pharma Ltd News

Why pharma stocks are emerging as safe bet amid global market turmoil

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Stocks to watch today: BPCL, Karnataka Bank, Hindalco, Mankind Pharma

Stocks to Watch today, May 20, 2026: BPCL, Karnataka Bank, Hindalco, Mankind Pharma, and JSW Energy are some of the key stocks to watch today

Mankind Pharma Q4 PAT rises 30% on strong domestic biz, chronic push

Mankind Pharma posted a 30.4% rise in Q4FY26 profit, driven by strong demand for chronic therapies and OTC healthcare products

Q4 results: BEL, BPCL, Mankind Pharma, Karnataka Bank, 122 more on May 19

Q4FY26 company results: Firms including Zydus Lifesciences, BASF India, PI Industries, Zee Entertainment, and Bosch Home Comfort India are also to release their January-March earnings today

Patent wins vs tariff risks: Analysts pick top pharma stocks to bet on

Pharma stocks have, so far, outperformed the markets in 2026. However, as risk around Trump tariffs resurface, analysts suggest shifting to domestic-focused companies. Here's the investment strategy.

Mankind Pharma shares gain 3% on acquiring Rivotril brand rights from Roche

The acquisition is expected to strengthen Mankind Pharma's presence in the central nervous system (CNS) segment and complement its existing neuro portfolio

Nifty Pharma index soars 7% thus far in February; nears 52-week high

Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.

Suzlon, Ola Electric, Bata, RPower, Wipro hit 52-week lows in firm market

Wipro, Cyient, Hexaware Technologies, KPIT Technologies and L&T Technology Services from the IT sector and Info Edge (India) and C.E. Info Systems from the IT-related sector hit 52-week lows on Monday

JM Financial flags growth concerns in Mankind Pharma; initiates with Reduce

JM Financial raised concerns around Mankind Pharma's recent BSV acquisition, which was executed at a high valuation and is expected to dilute return on capital

Mankind Pharma shares drop 4% even as Q3 profit rises; check outlook

Mankind Pharma recorded profit after tax (PAT) of ₹414 crore, up from ₹378 crore in the same quarter last year. Its revenue from operations also grew 11.5 per cent

Stocks to Watch: Bajaj Finance, Nazara Tech, Mankind Pharma, NBCC, Pidilite

Stocks to Watch today: Bajaj Finance, Nazara Technologies, Aditya Birla Capital, Mankind Pharma, Restaurant Brands Asia and NBCC are among the stocks to watch today, February 04, 2026

Mankind Pharma Q3 PAT up 9.5%, revenue rises 11.5% on chronic drugs sales

Mankind Pharma posted a 9.5 per cent rise in Q3FY26 net profit and 11.5 per cent growth in revenue, driven by strong domestic demand for chronic therapies

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,